(in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Current assets | ||||
Cash | $2971 | $1860 | $1401 | $1671 |
Short term investments | $82 | $76 | $77 | $86 |
Net receivables | $3765 | $3276 | $3261 | $3215 |
Inventory | $4843 | $4883 | $4593 | $4333 |
Total current assets | $12487 | $11045 | $10151 | $10155 |
Long term investments | ||||
Property, plant & equipment | $3215 | $3106 | $3082 | $3037 |
Goodwill & intangible assets | $19836 | $19869 | $20089 | $19628 |
Total noncurrent assets | $27394 | $26997 | $27258 | $26675 |
Total investments | $82 | $76 | $77 | $86 |
Total assets | $39881 | $38042 | $37409 | $36830 |
Current liabilities | ||||
Accounts payable | $1517 | $1296 | $1326 | $1366 |
Deferred revenue | ||||
Short long term debt | $2094 | $2308 | $1798 | $1204 |
Total current liabilities | $7890 | $7458 | $6584 | $5866 |
Long term debt | $10901 | $10382 | $11149 | $11857 |
Total noncurrent liabilities | $13398 | $12679 | $13464 | $14069 |
Total debt | $12995 | $12690 | $12947 | $13061 |
Total liabilities | $21288 | $20137 | $20048 | $19935 |
Shareholders' equity | ||||
Retained earnings | $16771 | $15933 | $15526 | $15072 |
Other shareholder equity | $18593 | -$249 | -$330 | -$305 |
Total shareholder equity | $18593 | $17905 | $17361 | $16895 |
(in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
---|---|---|---|---|
Current assets | ||||
Cash | $2971 | $1844 | $2944 | $2943 |
Short term investments | $82 | $84 | $75 | $81 |
Net receivables | $3765 | $3565 | $3022 | $2701 |
Inventory | $4843 | $3995 | $3314 | $3494 |
Total current assets | $12487 | $10275 | $10017 | $9707 |
Long term investments | ||||
Property, plant & equipment | $3215 | $2970 | $2833 | $2752 |
Goodwill & intangible assets | $19836 | $19765 | $17758 | $18332 |
Total noncurrent assets | $27394 | $26609 | $24614 | $24623 |
Total investments | $82 | $84 | $75 | $81 |
Total assets | $39881 | $36884 | $34631 | $34330 |
Current liabilities | ||||
Accounts payable | $1517 | $1413 | $1129 | $810 |
Deferred revenue | ||||
Short long term debt | $2094 | $1191 | $7 | $761 |
Total current liabilities | $7890 | $6303 | $4549 | $5041 |
Long term debt | $10901 | $11857 | $12472 | $13230 |
Total noncurrent liabilities | $13398 | $13965 | $15205 | $16205 |
Total debt | $12995 | $13048 | $12479 | $13991 |
Total liabilities | $21288 | $20268 | $19754 | $21246 |
Shareholders' equity | ||||
Retained earnings | $16771 | $14765 | $13480 | $12462 |
Other shareholder equity | $18593 | $16616 | -$531 | -$1157 |
Total shareholder equity | $18593 | $16616 | $14877 | $13084 |
(in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Revenue | ||||
Total revenue | $5815 | $4909 | $4996 | $4778 |
Cost of revenue | $1751 | $1815 | $1762 | |
Gross Profit | $3713 | $3158 | $3181 | $3016 |
Operating activities | ||||
Research & development | $353 | $346 | $339 | |
Selling, general & administrative | $1701 | $1706 | $1781 | |
Total operating expenses | $2278 | $2227 | $2216 | $2281 |
Operating income | $931 | $965 | $735 | |
Income from continuing operations | ||||
EBIT | $869 | $899 | $679 | |
Income tax expense | $83 | $177 | $161 | $87 |
Interest expense | ||||
Net income | ||||
Net income | $1143 | $692 | $738 | $592 |
Income (for common shares) | $692 | $738 | $592 |
(in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
---|---|---|---|---|
Revenue | ||||
Total revenue | $20498 | $18449 | $14351 | |
Cost of revenue | $6871 | $5294 | ||
Gross Profit | $13099 | $11578 | $9057 | |
Operating activities | ||||
Research & development | $1454 | $984 | ||
Selling, general & administrative | $6455 | $5361 | ||
Total operating expenses | $8779 | $8737 | $6834 | |
Operating income | $2841 | $2223 | ||
Income from continuing operations | ||||
EBIT | $2683 | $1954 | ||
Income tax expense | $508 | $325 | $355 | |
Interest expense | ||||
Net income | ||||
Net income | $3165 | $2358 | $1599 | |
Income (for common shares) | $2358 | $1599 |
(in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Net income | $692 | $738 | $592 | |
Operating activities | ||||
Depreciation | $98 | $98 | $96 | |
Business acquisitions & disposals | -$390 | |||
Stock-based compensation | $52 | $39 | $74 | |
Total cash flows from operations | $1050 | $688 | $445 | |
Investing activities | ||||
Capital expenditures | -$148 | -$152 | -$130 | |
Investments | $1 | $10 | -$3 | |
Total cash flows from investing | -$962 | -$145 | -$533 | -$132 |
Financing activities | ||||
Dividends paid | -$1139 | -$285 | -$285 | -$284 |
Sale and purchase of stock | ||||
Net borrowings | -$107 | -$103 | -$102 | |
Total cash flows from financing | -$1594 | -$422 | -$405 | -$481 |
Effect of exchange rate | -$28 | -$24 | -$20 | -$5 |
Change in cash and equivalents | $1096 | $459 | -$270 | -$173 |
(in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
---|---|---|---|---|
Net income | $2358 | $1994 | $1599 | |
Operating activities | ||||
Depreciation | $371 | $371 | $340 | |
Business acquisitions & disposals | -$2563 | -$339 | -$4222 | |
Stock-based compensation | $168 | $171 | $142 | |
Total cash flows from operations | $2624 | $3263 | $3277 | |
Investing activities | ||||
Capital expenditures | -$588 | -$525 | -$487 | |
Investments | $188 | $6 | $7 | |
Total cash flows from investing | -$962 | -$2924 | -$859 | -$4701 |
Financing activities | ||||
Dividends paid | -$1139 | -$1051 | -$950 | -$863 |
Sale and purchase of stock | ||||
Net borrowings | $472 | -$1153 | $989 | |
Total cash flows from financing | -$1594 | -$749 | -$2365 | -$11 |
Effect of exchange rate | -$28 | -$51 | -$38 | $41 |
Change in cash and equivalents | $1096 | -$1100 | $1 | -$1394 |
Here's Why Investors Should Retain STERIS (STE) Stock for Now
Zacks via Yahoo Finance
28 Mar 2024
|
Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now
Zacks via Yahoo Finance
27 Mar 2024
|
Stryker's (SYK) Latest Launch to Streamline Procedural Workflows
Zacks via Yahoo Finance
27 Mar 2024
|
Stryker's (NYSE:SYK) Dividend Will Be $0.80
Simply Wall St. via Yahoo Finance
26 Mar 2024
|
14 Best Medical Device Stocks To Buy Now
Insider Monkey via Yahoo Finance
24 Mar 2024
|
Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment
Zacks via Yahoo Finance
22 Mar 2024
|
Top Stock Reports for Disney, Morgan Stanley & Stryker
Zacks via Yahoo Finance
21 Mar 2024
|
Stryker Insiders Sell US$106m Of Stock, Possibly Signalling Caution
Simply Wall St. via Yahoo Finance
21 Mar 2024
|
Reasons to Add Stryker (SYK) Stock in Your Portfolio Now
Zacks
20 Mar 2024
|
Walgreens' (WBA) AllianceRx Pharmacy Will Distribute VIVJOA
Zacks via Yahoo Finance
20 Mar 2024
|
Market cap | $135.97B |
---|---|
Enterprise value | $145.99B |
Shares outstanding | 379.94M |
Revenue | $20.50B |
---|---|
EBITDA | N/A |
EBIT | N/A |
Net Income | $3.17B |
Revenue Q/Q | 11.78% |
Revenue Y/Y | 11.11% |
P/E ratio | 42.96 |
---|---|
EV/Sales | 7.12 |
EV/EBITDA | N/A |
EV/EBIT | N/A |
P/S ratio | 6.63 |
P/B ratio | InfinityT |
Book/Share | 0.00 |
Cash/Share | 7.82 |
EPS | $8.33 |
---|---|
ROA | 8.32% |
ROE | 17.89% |
Debt/Equity | 1.14 |
---|---|
Net debt/EBITDA | N/A |
Current ratio | 1.58 |
Quick ratio | 0.97 |